Lipitor, Atorvastatin

Lipitor, Atorvastatin Newswire (Page 5)

Comprehensive Real-Time News Feed for Lipitor, Atorvastatin (generic). (Page 5)

Results 81 - 100 of 771 in Lipitor, Atorvastatin (generic)

  1. Biotech Drug Savings of $250 Billion Close to Reaching U.S.Read the original story

    Sep 12, 2014 | The Washington Post

    At least 14 expensive biotechnology medicines that have never before faced generic rivals in the U.S. are being targeted by drugmakers who want to sell imitations at cheaper prices, according to regulators. For years, patients have been able to buy less expensive copies of existing chemical drugs -- ranging from Lipitor for cholesterol to the antidepressant Prozac -- once their patents ended.

    Comment?

  2. Why I'd Avoid Pfizer Inc. Stock Despite the DividendRead the original story

    Sep 11, 2014 | The Motley Fool

    Dividend stocks tend to be strong performers over the long term due to their ability to harness the awesome power of compounding returns. Even so, investors should always bear in mind that not all dividend stocks are good investments, even when they are associated with a strong brand.

    Comment?

  3. Losing Your Memory: It May be the Drugs You're TakingRead the original story w/Photo

    Sep 10, 2014 | Psychology Today

    Is memory loss interfering with your daily life? Most people are familiar with some of the things that can impair memory, including alcohol and drug abuse, head injuries, stroke, sleep deprivation, severe stress , aging or a symptom of conditions like Alzheimer's disease. What many do not know is that episodes of forgetfulness can also be side effects of prescription drugs.

    Comment?

  4. Ways to Spend Less on Prescription DrugsRead the original story w/Photo

    Aug 21, 2014 | Kiplinger Online

    As health insurers shift more of the cost burden to consumers, the average U.S. worker with employer-provided coverage now pays $9,695 per year in premiums and out-of-pocket costs for a family of four - a 118% increase over the past decade, according to the Milliman Medical Index. If you buy coverage on your own, you may be spending even more.

    Comment?

  5. Study indicates that statins may protect against microvascular complications of diabetesRead the original story w/Photo

    Sep 10, 2014 | PhysOrg Weblog

    The development of common diabetes complications that can lead to blindness and amputations could be reduced by taking statins, indicates new research published in The Lancet Diabetes & Endocrinology . It is well established that statins via cholesterol lowering effectively reduce the risks of heart attack and stroke in people with type 2 diabetes, but whether statin use affects the development of small blood vessel complications, such as eye, nerve, and kidney disease in individuals with diabetes is not known.

    Comment?

  6. Pharmacologic Inhibition of CXCL10 in Combination with Anti-malarial...Read the original story

    Sep 7, 2014 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Despite appropriate anti-malarial treatment, cerebral malaria -associated mortalities remain as high as 30%.

    Comment?

  7. US Acute Coronary Syndrome Drugs Industry (Antithrombotics,...Read the original story

    Sep 7, 2014 | Sys-Con Media

    MarketOptimizer.org adds "Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023", a new research report to its store. Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

    Comment?

  8. Use of ivabradine and atorvastatin in emergent orthopedic lower limb...Read the original story

    Sep 6, 2014 | Trials Journal

    The incidence of perioperative myocardial infarction globally is known to be around 2 to 3% and can prolong hospitalization, increased morbidity and mortality. Little is known about the pathophysiology and risk factors for PMI.

    Comment?

  9. Researchers to study effectiveness of atorvastatin in preventing...Read the original story w/Photo

    Sep 5, 2014 | Medical News

    Wake Forest Baptist Medical Center has been awarded $4.4 million to conduct a multiple-site clinical trial testing the effectiveness of a statin drug in preventing cardiovascular events in women treated for breast cancer. The National Heart, Lung and Blood Institute awarded Wake Forest Baptist $3 million for the project and the National Cancer Institute contributed $1.4 million.

    Comment?

  10. Pittsburgh coalition told unity will rein in health care costsRead the original story w/Photo

    Sep 4, 2014 | Pittsburgh Post-Gazette

    The "C-suite" executives - the chief executive officer, the chief financial officer and every other chief - must band together if they are to overcome the power of the health care industry and rein in health care costs. That was the message Thursday from Brian Klepper, CEO of the National Business Coalition on Health, who was the keynote speaker for Pittsburgh Business Group on Health's annual symposium at the Downtown Marriott.

    Comment?

  11. Researchers Receive $4.4 Million in Federal Funds to Determine If...Read the original story

    Sep 4, 2014 | Newswise

    Sept. 4, 2014 - Wake Forest Baptist Medical Center has been awarded $4.4 million to conduct a multiple-site clinical trial testing the effectiveness of a statin drug in preventing cardiovascular events in women treated for breast cancer. The National Heart, Lung and Blood Institute awarded Wake Forest Baptist $3 million for the project and the National Cancer Institute contributed $1.4 million.

    Comment?

  12. Is It Time to Buy Pfizer Inc.'s Stock?Read the original story w/Photo

    Sep 2, 2014 | The Motley Fool

    A combination of high-branded drug margins coupled with the expectation that the Affordable Care Act, better known as Obamacare, will translate into a long-term positive for the company have pushed its stock back near the $30 per share mark.

    Comment?

  13. Statin standoff: Does rosuvastatin tip the balance in diabetic patients?Read the original story w/Photo

    Sep 2, 2014 | Medical News Today

    When it comes to cholesterol-lowering statin medications for patients with type 2 diabetes , rosuvastatin may be a better choice than atorvastatin , according to the findings of a new study presented at ESC Congress 2014.

    Comment?

  14. South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as...Read the original story

    Sep 1, 2014 | Personal Injury Law News

    The Firm is evaluating potential Lipitor lawsuits on behalf of individuals who allegedly developed Lipitor diabetes injuries after taking the cholesterol-lowering statin drug.

    Comment?

  15. Biventricular pacing disappoints in BIOPACE trialRead the original story w/Photo

    Sep 1, 2014 | PhysOrg Weblog

    Biventricular pacing failed to significantly improve outcome compared to right ventricular pacing in patients with atrio-ventricular block according to preliminary results presented as a Hot Line at ESC Congress 2014.

    Comment?

  16. Experimental coronary stent combines ultrathin structure with biodegradable materialRead the original story w/Photo

    Sep 1, 2014 | PhysOrg Weblog

    A new generation of coronary artery stent that combines a biodegradable component with an ultrathin scaffold showed promising results compared with the current gold standard, in a large population of coronary artery disease patients, according to a new study.

    Comment?

  17. Investigational agent outshines ezetimibe for lowering cholesterolRead the original story w/Photo

    Sep 1, 2014 | PhysOrg Weblog

    The investigational drug alirocumab significantly improved cholesterol levels compared to ezetimibe, when added to regular statin therapy in patients with high cholesterol and elevated risk of cardiovascular disease , according to the ODYSSEY COMBO II trial, presented as a Hot Line today at ESC Congress 2014.

    Comment?

  18. New national guidelines can improve the way statin drugs are...Read the original story w/Photo

    Aug 29, 2014 | Medical News Today

    The research, recently published in the Journal of the American College of Cardiology , also showed the new guidelines produce only a modest increase in the number of patients being given the drugs.

    Comment?

  19. Amgen seeks approval for new cholesterol drugRead the original story

    Aug 28, 2014 | Pacific Business Times

    Amgen became the first drugmaker to seek U.S. regulatory approval for a new class of cholesterol-lowering treatments after it submitted an application to the Food and Drug Administration on Thursday for evolocumab.

    Comment?

  20. UPDATE 1-Amgen seeks U.S. approval of new cholesterol-fighting drugRead the original story

    Aug 28, 2014 | Reuters

    Amgen Inc said on Thursday it applied to U.S. health regulators to sell its cholesterol fighter, evolocumab, becoming the first company to seek approval of a medicine from a closely watched new class of potent heart drugs.

    Comment?